Alto Neuroscience (NYSE:ANRO) Rating Lowered to “Sell” at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also commented on ANRO. Chardan Capital restated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research report on Tuesday, March 17th. Wedbush raised their price target on shares of Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, March 17th. Robert W. Baird upped their price objective on shares of Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research note on Wednesday, March 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $21.38 on Friday. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $25.17. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average of $18.47 and a two-hundred day moving average of $13.74. The company has a market capitalization of $683.12 million, a price-to-earnings ratio of -9.81 and a beta of 2.51.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. As a group, analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several large investors have recently added to or reduced their stakes in ANRO. Invesco Ltd. bought a new position in shares of Alto Neuroscience during the 1st quarter valued at $67,000. AQR Capital Management LLC bought a new stake in Alto Neuroscience in the first quarter worth $52,000. Bank of Montreal Can bought a new stake in Alto Neuroscience in the second quarter worth $25,000. AlphaCore Capital LLC increased its position in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after buying an additional 84,417 shares during the last quarter.

Alto Neuroscience News Roundup

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Robert W. Baird raised its price target to $41, which can support upside sentiment and buying interest for growth/biotech investors. Robert W. Baird Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $41.00
• Positive Sentiment: Wedbush reiterated a constructive outlook for Alto and flagged potential strong price appreciation, supporting demand from momentum/coverage-driven buyers. Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating, another supportive analyst signal for investor confidence. Chardan Capital Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)
• Neutral Sentiment: Recent quarterly report (Mar 16) slightly beat EPS consensus, which provides some fundamental support versus the negative estimate revisions. Alto Neuroscience — Company Page
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions (Mar 18) to Alto’s near- and medium-term EPS: Q1 2026 to ($0.63) from ($0.59), Q2 2026 to ($0.67) from ($0.64), Q4 2026 to ($0.74) (earlier view higher), FY2026 to ($2.75) from ($2.51), and sharper cuts to FY2027–FY2029/FY2028 (e.g., FY2028 to ($4.11) from ($2.65); FY2029 to ($2.99) from ($1.54)). These more bearish earnings trajectories increase uncertainty on cash burn and timing to profitability, which likely explains much of the downward pressure on the stock today. HC Wainwright Lowers Earnings Estimates for Alto Neuroscience

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.